文章预览
SCI 12 December 2025 Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03 (Journal of Thoracic Oncology; IF:21.1) Please cite this article as: Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A, Sullivan IG, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar SN, Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03, Journal of Thoracic Oncology (2025), doi: https://doi.org/10.1016/j.jtho.2024.12.028. Correspondence to : Afshin Dowlati, MD, University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106. Email: Afshin.dowlati@uhhospitals.org Introduction: 摘要 The phase 2 TROPiCS-03 study evaluated the efficacy/safety of Sacituzumab govitecan (SG) as second-line treatment in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). 2
………………………………
